Table 3.
Comparison between plasma lipid changes induced by monotherapy with BBR/P/RR (n. 14 subjects) or EZE (n. 12 subjects) and combined therapy with BBR/P/RR plus EZE in HCH patients
| Lipid parameter | Baseline | Monotherapy | % changes | Combined therapy | % changes | ‡P |
|---|---|---|---|---|---|---|
| TC (mmol/L) |
7.74 ± 0.40 |
6.34 ± 0.40* |
−18.0 ± 3.5 |
5.59 ± 0.40† |
−27.7 ± 3.8 |
< 0.001 |
| LDL-C (mmol/L) |
5.47 ± 0.51 |
4.19 ± 0.48* |
−23.5 ± 3.5 |
3.44 ± 0.44† |
−37.1 ± 4.5 |
< 0.001 |
| HDL-C (mmol/L) |
1.58 ± 0.40 |
1.59 ± 0.42 |
+0.17 ± 8.2 |
1.60 ± 0.42 |
+1.10 ± 5.7 |
NS |
| non-HDL-C (mmol/L) |
6.15 ± 0.59 |
4.75 ± 0.57* |
−22.8 ± 3.8 |
3.98 ± 0.49† |
−35.3 ± 4.2 |
< 0.001 |
| TG (mmol/L) | 1.48 (1.08-1.89) | 1.12 (0.95-1.47)* | −18.6 ± 15.5 | 1.09 (0.94-1.35)† | −23.1 ± 12.9 | < 0.005 |
Values are means ± SD or medians (interquartile ranges). *P <0.001 vs baseline values and †P <0.001 vs monotherapy; ‡P: significance of the differences between percent changes induced by monotherapy and by combined therapy (Student’s t test for paired data or Wilcoxon test, respectively). NS: not significant.